c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma

Oncotarget

Volumn 7, Issue 40, 2016, Pages 65514-65539

  Ciribilli, Yari ^a   Singh, Prashant ^b   Inga, Alberto ^a   Borlak, Jürgen ^b  

^a UNIVERSITY OF TRENTO   (Italy)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

C Myc DNA binding activity; C Myc targeted regulators of cellular growth; c Myc transgenic mouse model of papillary lung adenocarcinomas; Regulatory gene networks; Whole genome transcriptome profiling

Indexed keywords

ARGININE; CYCLIN DEPENDENT KINASE 4; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; FATTY ACID SYNTHASE; FOLATE TRANSPORTER; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEXOKINASE; HEXOKINASE 1; MYC PROTEIN; NUCLEOLIN; NUCLEOPHOSMIN; NUCLEOPLASMIN 3; RIBONUCLEOPROTEIN; RIBOSOMAL PROTEIN SA; RNA TERMINAL PHOSPHATE CYCLASE LIKE 1; TRIOSEPHOSPHATE ISOMERASE; TUMOR PROMOTER; UNCLASSIFIED DRUG; URIDINE KINASE; HK1 PROTEIN, HUMAN; LAMININ RECEPTOR; MYC PROTEIN, MOUSE; NPM3 PROTEIN, HUMAN; NUCLEOPLASMIN; REDUCED FOLATE CARRIER; RIBOSOME PROTEIN; RPSA PROTEIN, HUMAN; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL MODEL; ARG1 GENE; ARTICLE; AUXOTROPHY; BINDING SITE; BIOGENESIS; CARBOHYDRATE METABOLISM; CELL METABOLISM; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA BINDING; DNA METABOLISM; DNA REPAIR; FASN GENE; GEL MOBILITY SHIFT ASSAY; GENE CONSTRUCT; GENE MAPPING; GENOMIC INSTABILITY; HK2 GENE; HUMAN; HUMAN CELL; IMPDH2 GENE; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; NPM3 GENE; PAPILLARY CARCINOMA; PAPILLARY LUNG ADENOCARCINOMA; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; RIBOSOME; RNA PROCESSING; SATB1 GENE; SHTM1 GENE; SLC19A1 GENE; SMARCC1 GENE; SRM1 GENE; TK1 GENE; TUMOR GENE; UCK2 GENE; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; BIOLOGY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; LUNG TUMOR; METABOLISM; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADENOCARCINOMA, PAPILLARY; ANIMALS; BINDING SITES; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HEXOKINASE; HUMANS; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; NUCLEOPLASMINS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, LAMININ; REDUCED FOLATE CARRIER PROTEIN; RIBOSOMAL PROTEINS; TRANSCRIPTOME;

EID: 84994092307     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11804     Document Type: Article

References (89)

1. Centers for Disease Control and Prevention. Fact sheet Smoking & Tobacco Use. 2016.
2. World Health Organization. Fact sheet no 339-Tobacco.
3. Charloux A, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. International journal of epidemiology. 1997; 26:14-23.
4. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: MarvelouslY Complex. Advances in Cancer Research. 2002; 84:81-154.
5. Geng Z, Zhang D, Liu Y. Expression of telomerase hTERT in human non-small cell lung cancer and its correlation with c-Myc gene. Chinese medical journal. 2003; 116:1467-1470.
6. Tsai LH, Wu JY, Cheng YW, Chen CY, Sheu GT, Wu TC, Lee H. The MZF1/c-Myc axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss. Oncogene. 2015; 34:1641-1649.
7. Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M. MAX inactivation in small cell lung cancer disrupts MYCSWI/SNF programs and is synthetic lethal with BRG1. Cancer discovery. 2014; 4:292-303.
8. Sears RC. The life cycle of C-Myc: from synthesis to degradation. Cell cycle (Georgetown, Tex.). 2004; 3:1133-1137.
9. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B. Genomic targets of the human c-Myc protein. Genes & development. 2003; 17:1115-1129.
10. Patel JH, Loboda AP, Showe MK, Showe LC, McMahon SB. Analysis of genomic targets reveals complex functions of MYC. Nature reviews. Cancer. 2004; 4:562-568.
11. Ehrhardt A, Bartels T, Geick A, Klocke R, Paul D, Halter R. Development of pulmonary bronchiolo-alveolar adenocarcinomas in transgenic mice overexpressing murine c-Myc and epidermal growth factor in alveolar type II pneumocytes. British journal of cancer. 2001; 84:813-818.
12. Ciribilli Y, Singh P, Spanel R, Inga A, Borlak J. Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas. Oncotarget. 2015; 6:31569-31592. doi: 10.18632/oncotarget.5035.
13. Menssen A, Hermeking H. Characterization of the c-Mycregulated transcriptome by SAGE: identification and analysis of c-Myc target genes. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99:6274-6279.
14. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome biology. 2003; 4:R69.
15. Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, Yustein JT, Ooi HS, Orlov YL, Shahab A, Yong HC, Fu Y, Weng Z, Kuznetsov VA, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:17834-17839.
16. Reymann S, Borlak J. Transcription profiling of lung adenocarcinomas of c-Myc-transgenic mice: identification of the c-Myc regulatory gene network. BMC systems biology. 2008; 2:46.
17. Reamon-Buettner SM, Borlak J. Epigenetic silencing of cell adhesion molecule 1 in different cancer progenitor cells of transgenic c-Myc and c-Raf mouse lung tumors. Cancer research. 2008; 68:7587-7596.
18. Sabo A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, Morelli MJ, Bora P, Doni M, Verrecchia A, Tonelli C, Faga G, Bianchi V, et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature. 2014; 511:488-492.
19. Walz S, Lorenzin F, Morton J, Wiese KE, von Eyss B, Herold S, Rycak L, Dumay-Odelot H, Karim S, Bartkuhn M, Roels F, Wustefeld T, Fischer M, et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature. 2014; 511:483-487.
20. Szasz AM, Lanczky A, Nagy A, Forster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabo A, Gyorffy B. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1, 065 patients. Oncotarget. 2016. doi: 10.18632/oncotarget.10337.
21. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clinical cancer research. 2009; 15:6479-6483.
22. Phillips MM, SheaffMT, Szlosarek PW. Targeting argininedependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer research and treatment. 2013; 45:251-262.
23. Garber K. Energy boost: the Warburg effect returns in a new theory of cancer. Journal of the National Cancer Institute. 2004; 96:1805-1806.
24. Furuta E, Okuda H, Kobayashi A, Watabe K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochimica et biophysica acta. 2010; 1805:141-152.
25. Westphal D, Kluck RM, Dewson G. Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell death and differentiation. 2014; 21:196-205.
26. Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, Jha AK, Smolen GA, Clasquin MF, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer cell. 2013; 24:213-228.
27. Guo C, Liu S, Sun MZ. Novel insight into the role of GAPDH playing in tumor. Clinical & translational oncology. 2013; 15:167-172.
28. Smith TA. Mammalian hexokinases and their abnormal expression in cancer. British journal of biomedical science. 2000; 57:170-178.
29. Puzone R, Savarino G, Salvi S, Dal Bello MG, Barletta G, Genova C, Rijavec E, Sini C, Esposito AI, Ratto GB, Truini M, Grossi F, Pfeffer U. Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients. Molecular cancer. 2013; 12:97-4598-12-97.
30. Tsutsumi S, Yanagawa T, Shimura T, Kuwano H, Raz A. Autocrine motility factor signaling enhances pancreatic cancer metastasis. Clinical cancer research. 2004; 10: 7775-7784.
31. Takanami I, Takeuchi K, Naruke M, Kodaira S, Tanaka F, Watanabe H, Raz A. Autocrine motility factor in pulmonary adenocarcinomas: results of an immunohistochemical study. Tumour biology. 1998; 19:384-389.
32. Swinnen JV, Van Veldhoven PP, Timmermans L, De Schrijver E, Brusselmans K, Vanderhoydonc F, Van de Sande T, Heemers H, Heyns W, Verhoeven G. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochemical and biophysical research communications. 2003; 302:898-903.
33. Evert M, Schneider-Stock R, Dombrowski F. Overexpression of fatty acid synthase in chemically and hormonally induced hepatocarcinogenesis of the rat. Laboratory investigation; a journal of technical methods and pathology. 2005; 85:99-108.
34. Brusselmans K, Vrolix R, Verhoeven G, Swinnen JV. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. The Journal of biological chemistry. 2005; 280:5636-5645.
35. Pullamsetti SS, Banat GA, Schmall A, Szibor M, Pomagruk D, Hanze J, Kolosionek E, Wilhelm J, Braun T, Grimminger F, Seeger W, Schermuly RT, Savai R. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene. 2013; 32:1121-1134.
36. Nair VS, Gevaert O, Davidzon G, Plevritis SK, West R. NFkappaB protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer:a radiogenomics validation study to understand tumor metabolism. Lung cancer (Amsterdam, Netherlands). 2014; 83:189-196.
37. Luo F, Liu X, Yan N, Li S, Cao G, Cheng Q, Xia Q, Wang H. Hypoxia-inducible transcription factor-1alpha promotes hypoxia-induced A549 apoptosis via a mechanism that involves the glycolysis pathway. BMC cancer. 2006; 6:26.
38. Semenza GL. Targeting HIF-1 for cancer therapy. Nature reviews. Cancer. 2003; 3:721-732.
39. Zhang Y, Li M, Liu Y, Han N, Zhang K, Xiao T, Cheng S, Gao Y. ENO1 protein levels in the tumor tissues and circulating plasma samples of non-small cell lung cancer patients. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2010; 13:1089-1093.
40. Chang YS, Wu W, Walsh G, Hong WK, Mao L. Enolasealpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clinical cancer research. 2003; 9:3641-3644.
41. Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, Hofstetter W, Kalhor N, Lee JJ, Franklin W, Stewart DJ, Wistuba II. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. Journal of thoracic oncology. 2012; 7:833-840.
42. Shen M, Rothman N, Berndt SI, He X, Yeager M, Welch R, Chanock S, Caporaso N, Lan Q. Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei, China. Lung cancer (Amsterdam, Netherlands). 2005; 49:299-309.
43. Herbig K, Chiang EP, Lee LR, Hills J, Shane B, Stover PJ. Cytoplasmic serine hydroxymethyltransferase mediates competition between folate-dependent deoxyribonucleotide and S-adenosylmethionine biosyntheses. The Journal of biological chemistry. 2002; 277:38381-38389.
44. Wang L, Lu J, An J, Shi Q, Spitz MR, Wei Q. Polymorphisms of cytosolic serine hydroxymethyltransferase and risk of lung cancer:a case-control analysis. Lung cancer (Amsterdam, Netherlands). 2007; 57:143-151.
45. Swartz MD, Peterson CB, Lupo PJ, Wu X, Forman MR, Spitz MR, Hernandez LM, Vannucci M, Shete S. Investigating multiple candidate genes and nutrients in the folate metabolism pathway to detect genetic and nutritional risk factors for lung cancer. PloS one. 2013; 8:e53475.
46. Ulrich CM, Reed MC, Nijhout HF. Modeling folate, onecarbon metabolism, and DNA methylation. Nutrition reviews. 2008; 66:S27-30.
47. Matakidou A, El Galta R, Rudd MF, Webb EL, Bridle H, Eisen T, Houlston RS. Prognostic significance of folate metabolism polymorphisms for lung cancer. British journal of cancer. 2007; 97:247-252.
48. Paone A, Marani M, Fiascarelli A, Rinaldo S, Giardina G, Contestabile R, Paiardini A, Cutruzzola F. SHMT1 knockdown induces apoptosis in lung cancer cells by causing uracil misincorporation. Cell death & disease. 2014; 5:e1525.
49. Liu J, Schmitz JC, Lin X, Tai N, Yan W, Farrell M, Bailly M, Chen T, Chu E. Thymidylate synthase as a translational regulator of cellular gene expression. Biochimica et biophysica acta. 2002; 1587:174-182.
50. Shi Q, Zhang Z, Neumann AS, Li G, Spitz MR, Wei Q. Case-control analysis of thymidylate synthase polymorphisms and risk of lung cancer. Carcinogenesis. 2005; 26:649-656.
51. Li HX, Lei DS, Wang XQ, Skog S, He Q. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncology reports. 2005; 13:145-149.
52. Greengard O, Head JF, Goldberg SL. Uridine kinase, adenylate kinase, and guanase in human lung tumors. Cancer research. 1980; 40:2295-2299.
53. D'Angiolella V, Donato V, Forrester FM, Jeong YT, Pellacani C, Kudo Y, Saraf A, Florens L, Washburn MP, Pagano M. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell. 2012; 149:1023-1034.
54. Zhang YW, Jones TL, Martin SE, Caplen NJ, Pommier Y. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. The Journal of biological chemistry. 2009; 284:18085-18095.
55. Rahman MA, Amin AR, Wang D, Koenig L, Nannapaneni S, Chen Z, Wang Z, Sica G, Deng X, Chen ZG, Shin DM. RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. Clinical cancer research. 2013; 19:3416-3428.
56. 1 H3K9me3 HMTase in human lung cancer cells. Biochemical and biophysical research communications. 2013; 438:647-652.
57. Gautschi O. The polyamine metabolism: renaissance of an old pathway in oncology. Clinical lung cancer. 2010; 11:80-81.
58. Grimminger PP, Schneider PM, Metzger R, Vallbohmer D, Danenberg KD, Danenberg PV, Holscher AH, Brabender J. Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer. Clinical lung cancer. 2010; 11:114-119.
59. Gerner EW. Cancer chemoprevention locks onto a new polyamine metabolic target. Cancer prevention research (Philadelphia, Pa.). 2010; 3:125-127.
60. Shah N, Thomas TJ, Lewis JS, Klinge CM, Shirahata A, Gelinas C, Thomas T. Regulation of estrogenic and nuclear factor kappa B functions by polyamines and their role in polyamine analog-induced apoptosis of breast cancer cells. Oncogene. 2001; 20:1715-1729.
61. van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nature reviews. Cancer. 2010; 10:301-309.
62. Wu M, Tu T, Huang Y, Cao Y. Suppression subtractive hybridization identified differentially expressed genes in lung adenocarcinoma: ERGIC3 as a novel lung cancerrelated gene. BMC cancer. 2013; 13:44-2407-13-44.
63. Koga M, Shichijo S, Yamada A, Ashihara J, Sawamizu H, Kusukawa J, Itoh K. Identification of ribosomal proteins S2 and L10a as tumor antigens recognized by HLA-A26-restricted CTL. Tissue antigens. 2003; 61:136-145.
64. Russo N, Wang X, Liu M, Banerjee R, Goto M, Scanlon C, Metwally T, Inglehart RC, Tsodikov A, Duffy S, Van Tubergen E, Bradford C, Carey T, et al. A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature. Oncogene. 2013; 32:5026-5037.
65. Kim JH, You KR, Kim IH, Cho BH, Kim CY, Kim DG. Over-expression of the ribosomal protein L36a gene is associated with cellular proliferation in hepatocellular carcinoma. Hepatology (Baltimore, Md.). 2004; 39:129-138.
66. Cowling VH, Turner SA, Cole MD. Burkitt's lymphomaassociated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis. Oncogene. 2014; 33:3519-3527.
67. Mei YP, Liao JP, Shen J, Yu L, Liu BL, Liu L, Li RY, Ji L, Dorsey SG, Jiang ZR, Katz RL, Wang JY, Jiang F. Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis. Oncogene. 2012; 31:2794-2804.
68. Renieri A, Mencarelli MA, Cetta F, Baldassarri M, Mari F, Furini S, Piu P, Ariani F, Dragani TA, Frullanti E. Oligogenic germline mutations identified in early nonsmokers lung adenocarcinoma patients. Lung cancer (Amsterdam, Netherlands). 2014; 85:168-174.
69. Grisendi S, Mecucci C, Falini B, PandolfiPP. Nucleophosmin and cancer. Nature reviews. Cancer. 2006; 6:493-505.
70. Mendes-da-Silva P, Moreira A, Duro-da-Costa J, Matias D, Monteiro C. Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma. Molecular pathology. 2000; 53:184-187.
71. Pang Q, Christianson TA, Koretsky T, Carlson H, David L, Keeble W, Faulkner GR, Speckhart A, Bagby GC. Nucleophosmin interacts with and inhibits the catalytic function of eukaryotic initiation factor 2 kinase PKR. The Journal of biological chemistry. 2003; 278:41709-41717.
72. Greasley PJ, Bonnard C, Amati B. Myc induces the nucleolin and BN51 genes:possible implications in ribosome biogenesis. Nucleic acids research. 2000; 28:446-453.
73. Ding Y, Song N, Liu C, He T, Zhuo W, He X, Chen Y, Song X, Fu Y, Luo Y. Heat shock cognate 70 regulates the translocation and angiogenic function of nucleolin. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012; 32:e126-34.
74. Tsou JH, Chang KY, Wang WC, Tseng JT, Su WC, Hung LY, Chang WC, Chen BK. Nucleolin regulates c-Jun/Sp1-dependent transcriptional activation of cPLA2alpha in phorbol ester-treated non-small cell lung cancer A549 cells. Nucleic acids research. 2008; 36:217-227.
75. Wang D, Xiang DB, Yang XQ, Chen LS, Li MX, Zhong ZY, Zhang YS. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung cancer (Amsterdam, Netherlands). 2009; 66:298-304.
76. Seo SB, Macfarlan T, McNamara P, Hong R, Mukai Y, Heo S, Chakravarti D. Regulation of histone acetylation and transcription by nuclear protein pp32, a subunit of the INHAT complex. The Journal of biological chemistry. 2002; 277:14005-14010.
77. Schramedei K, Morbt N, Pfeifer G, Lauter J, Rosolowski M, Tomm JM, von Bergen M, Horn F, Brocke-Heidrich K. MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Oncogene. 2011; 30:2975-2985.
78. Shen F, Look KY, Yeh YA, Weber G. Increased uridine kinase (ATP: uridine 5'-phosphotransferase; EC 2.7.1.48) activity in human and rat tumors. Cancer biochemistry biophysics. 1998; 16:1-15.
79. Goel A, Mathupala SP, Pedersen PL. Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. The Journal of biological chemistry. 2003; 278:15333-15340.
80. Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K. Two distinct cDNAs for human IMP dehydrogenase. The Journal of biological chemistry. 1990; 265:5292-5295.
81. Wikman H, Kettunen E, Seppanen JK, Karjalainen A, Hollmen J, Anttila S, Knuutila S. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene. 2002; 21:5804-5813.
82. Suer Gokmen S, Yoruk Y, Cakir E, Yorulmaz F, Gulen S. Arginase and ornithine, as markers in human non-small cell lung carcinoma. Cancer biochemistry biophysics. 1999; 17:125-131.
83. Nakagawa T, Otake Y, Yanagihara K, Miyahara R, Ishikawa S, Fukushima M, Wada H, Tanaka F. Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands). 2004; 43:145-149.
84. Rotenberg Z, Weinberger I, Sagie A, Fuchs J, Davidson E, Sperling O, Agmon J. Total lactate dehydrogenase and its isoenzymes in serum of patients with non-small-cell lung cancer. Clinical chemistry. 1988; 34:668-670.
85. Temme A, Rieger M, Reber F, Lindemann D, Weigle B, Diestelkoetter-Bachert P, Ehninger G, Tatsuka M, Terada Y, Rieber EP. Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell. Molecular biology of the cell. 2003; 14:78-92.
86. Bisio A, Zamborszky J, Zaccara S, Lion M, Tebaldi T, Sharma V, Raimondi I, Alessandrini F, Ciribilli Y, Inga A. Cooperative interactions between p53 and NFkappaB enhance cell plasticity. Oncotarget. 2014; 5:12111-12125. doi: 10.18632/oncotarget.2545.
87. Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PloS one. 2013; 8:e82241.
88. 1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells. Cancer cell international. 2013; 13:8-2867-13-8.
89. Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, McCaughan BC, Stirzaker C, Kohonen-Corish MR. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. Journal of thoracic oncology. 2011; 6:1179-1189.